Why a Toxicology Paper Matters for a Sleep Supplement

When a new ingredient enters the nutraceutical market, it is typically accompanied by two types of evidence: efficacy data (does it work?) and safety data (is it well-tolerated?). The clinical trials on Maizinol have covered efficacy thoroughly - two independent, randomised, placebo-controlled human trials measuring deep sleep gains of up to 30 additional minutes per night, and cortisol reduction of up to 36%.

But efficacy and safety are separate questions, and they require separate evidence. A dedicated toxicology study asks a different question: what happens to the body when this compound is administered repeatedly over time, at doses higher than the intended human dose?

That study has now been published. And the answer is: nothing of concern.

What Is an Oral Subchronic Toxicology Study?

"Subchronic" refers to repeated dosing over an extended period - typically 90 days in regulatory toxicology. "Oral" means the compound was administered by mouth, matching the route of human supplementation. This study design is specifically intended to detect whether repeated, high-dose oral exposure causes any cumulative harm to tissues or organs.

The key parameters evaluated in this type of study include body weight and feed consumption, organ weights (liver, kidney, heart, spleen), haematological markers (red blood cells, white blood cells, platelets), clinical chemistry (liver enzymes, kidney function markers, blood glucose), and histopathological examination of tissues under a microscope.

If an ingredient causes harm through repeated use - even harm that is not immediately obvious - this is the study design that finds it.

What the Study Found

The study - Weston et al., published in the Journal of Applied Toxicology (DOI: 10.1002/jat.4882, PMID: 40988153) - evaluated Maizinol (UP165), the standardised corn-leaf extract manufactured by Unigen Inc. The conclusion: safety confirmed at tested doses, with no significant adverse findings.

This builds on the safety evidence that preceded it:

Test Type	What Was Assessed	Finding
Ames Test (in vitro)	Mutagenicity - does the compound alter DNA?	No mutagenic activity
Chromosomal Aberration Assay	Clastogenicity - does it cause chromosome breaks?	No clastogenic activity
Preclinical Animal Studies	Organ, blood, and tissue effects at high doses	No adverse effects
Oral Subchronic Toxicology Weston et al., J. Appl. Toxicol.	Repeated oral dosing over extended period; organ and tissue evaluation	Safe - no significant findings
Human RCT #1 Talbott et al., 2022. 42 participants.	Adverse events in 4-week human trial	No serious adverse events
Human RCT #2 KGK Science/Unigen, 2025. 80 participants.	Adverse events in 28-day EEG-monitored trial	No serious adverse events

Across all six evidence types - from bench to clinical trial - no significant safety concern has been identified for Maizinol at doses consistent with supplementation use.

What the Human Trials Showed on Safety

The two clinical trials on Maizinol produced a combined 122 human participants dosed repeatedly over 4 weeks. Their safety findings are the most directly relevant to people considering the ingredient. For the full efficacy data from both trials, see the Night Reboot clinical evidence page.

The second trial - a triple-blind, EEG-measured study conducted by KGK Science - was particularly rigorous on the question of circadian disruption. One of the legitimate safety concerns with any sleep ingredient is whether it shifts the body clock in ways that cause long-term problems. Melatonin, for example, can phase-shift the circadian rhythm when taken at the wrong time or in excess doses.

Maizinol produced no such effect. Sleep architecture improved - more deep NREM sleep, reduced sleep latency, fewer nighttime awakenings - without any measurable change to circadian phase. The body's internal clock was entirely undisturbed.

Why Non-Habit-Forming Matters Here

Safety is not only about acute toxicity. For a sleep ingredient, the question of habit formation and dependency is equally important - perhaps more so, given that many conventional sleep aids carry significant dependency risks.

Maizinol's mechanism makes dependency biologically unlikely. It works by stimulating the enzymatic machinery your pineal gland uses to produce melatonin - specifically the enzymes tryptophan hydroxylase and N-acetyltransferase. This is upstream stimulation of a natural biosynthetic process, not receptor hijacking.

Benzodiazepines and Z-drugs cause dependency because they are full agonists at GABA-A receptors: the receptor adapts to their presence and requires them to function normally. Maizinol does not work this way. It has partial GABA-A activity, but its primary mechanism is biosynthetic - encouraging the body to make more of its own melatonin rather than replacing it.

How This Fits Into Reincarn Night Reboot

Reincarn Night Reboot uses Maizinol UP165 as its lead deep sleep ingredient, at the clinically studied dose. Every other ingredient in the stack - Glycine (3,000 mg), Magnesium Bisglycinate (200 mg elemental), L-Theanine (200 mg), Tart Cherry Extract (400 mg), Tagara Root (250 mg), and Vitamin B6 as P5P (2 mg) - has an established safety record in published literature at the doses used.

The full formula is manufactured by Siddhayu Life Sciences (part of the Baidyanath Group) in a GMP-certified, ISO-certified, and FSSAI-approved facility. The product contains no melatonin, no sedatives, no scheduled substances under Indian law, and no ingredients associated with dependency or tolerance.

This toxicology study closes a gap that we believe matters for our customers: you should be able to look at every piece of evidence behind an ingredient, not just the efficacy headlines.

Frequently Asked Questions